Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 150

1.

Selectivity of compounds isolated from the leaves of Nerium indicum Mill. on various human cancer cell lines.

Mae SH, Sofia M, Bolhuis RL, Nooter K, Oostrum RG, Subagus W, Ibnu GG.

Med J Malaysia. 2008 Jul;63 Suppl A:24-5.

PMID:
19024965
2.

The development of novel organotin anti-tumor drugs: structure and activity.

de Vos D, Willem R, Gielen M, van Wingerden KE, Nooter K.

Met Based Drugs. 1998;5(4):179-88. doi: 10.1155/MBD.1998.179.

3.

Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib.

Gardner ER, Burger H, van Schaik RH, van Oosterom AT, de Bruijn EA, Guetens G, Prenen H, de Jong FA, Baker SD, Bates SE, Figg WD, Verweij J, Sparreboom A, Nooter K.

Clin Pharmacol Ther. 2006 Aug;80(2):192-201.

PMID:
16890580
4.

Functional screen for genes responsible for tamoxifen resistance in human breast cancer cells.

Meijer D, van Agthoven T, Bosma PT, Nooter K, Dorssers LC.

Mol Cancer Res. 2006 Jun;4(6):379-86.

5.

Impaired cisplatin influx in an A2780 mutant cell line: evidence for a putative, cis-configuration-specific, platinum influx transporter.

Helleman J, Burger H, Hamelers IH, Boersma AW, de Kroon AI, Stoter G, Nooter K.

Cancer Biol Ther. 2006 Aug;5(8):943-9. Epub 2006 Aug 2.

PMID:
16775422
6.

Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values.

Loos WJ, de Jongh FE, Sparreboom A, de Wit R, van Boven-van Zomeren DM, Stoter G, Nooter K, Verweij J.

J Clin Oncol. 2006 Apr 1;24(10):1499-506.

PMID:
16574999
7.

A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors.

Felici A, Loos WJ, Verweij J, Cirillo I, de Bruijn P, Nooter K, Mathijssen RH, de Jonge MJ.

Cancer Chemother Pharmacol. 2006 Nov;58(5):673-80. Epub 2006 Mar 17.

PMID:
16544143
8.

Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes.

Burger H, den Bakker MA, Kros JM, van Tol H, de Bruin AM, Oosterhuis W, van den Ingh HF, van der Harst E, de Schipper HP, Wiemer EA, Nooter K.

Cancer Biol Ther. 2005 Nov;4(11):1270-4. Epub 2005 Nov 18.

PMID:
16294026
9.

Molecular profiling of platinum resistant ovarian cancer.

Helleman J, Jansen MP, Span PN, van Staveren IL, Massuger LF, Meijer-van Gelder ME, Sweep FC, Ewing PC, van der Burg ME, Stoter G, Nooter K, Berns EM.

Int J Cancer. 2006 Apr 15;118(8):1963-71. Erratum in: Int J Cancer. 2006 Aug 1;119(3):726.

10.

Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps.

Burger H, van Tol H, Brok M, Wiemer EA, de Bruijn EA, Guetens G, de Boeck G, Sparreboom A, Verweij J, Nooter K.

Cancer Biol Ther. 2005 Jul;4(7):747-52. Epub 2005 Jul 9.

PMID:
15970668
11.

Effect of ABCG2 genotype on the oral bioavailability of topotecan.

Sparreboom A, Loos WJ, Burger H, Sissung TM, Verweij J, Figg WD, Nooter K, Gelderblom H.

Cancer Biol Ther. 2005 Jun;4(6):650-8. Epub 2005 Jun 11.

PMID:
15908806
12.

Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2.

Lepper ER, Nooter K, Verweij J, Acharya MR, Figg WD, Sparreboom A.

Pharmacogenomics. 2005 Mar;6(2):115-38. Review.

PMID:
15882131
13.
14.

Resistance to platinum-containing chemotherapy in testicular germ cell tumors is associated with downregulation of the protein kinase SRPK1.

Schenk PW, Stoop H, Bokemeyer C, Mayer F, Stoter G, Oosterhuis JW, Wiemer E, Looijenga LH, Nooter K.

Neoplasia. 2004 Jul-Aug;6(4):297-301.

15.

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump.

Burger H, van Tol H, Boersma AW, Brok M, Wiemer EA, Stoter G, Nooter K.

Blood. 2004 Nov 1;104(9):2940-2. Epub 2004 Jul 13.

PMID:
15251980
16.

Functional cloning of drug resistance genes from retroviral cDNA libraries.

Bosma PT, van Eert SJ, Jaspers NG, Stoter G, Nooter K.

Biochem Biophys Res Commun. 2003 Sep 26;309(3):605-11.

PMID:
12963033
17.

Anticancer drug resistance induced by disruption of the Saccharomyces cerevisiae NPR2 gene: a novel component involved in cisplatin- and doxorubicin-provoked cell kill.

Schenk PW, Brok M, Boersma AW, Brandsma JA, Den Dulk H, Burger H, Stoter G, Brouwer J, Nooter K.

Mol Pharmacol. 2003 Aug;64(2):259-68.

PMID:
12869630
18.

Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens.

Burger H, den Bakker MA, Stoter G, Verweij J, Nooter K.

Eur J Cancer. 2003 Apr;39(6):793-9.

PMID:
12651205
19.

Red blood cells: a neglected compartment in topotecan pharmacokinetic analysis.

Loos WJ, Gelderblom H, Verweij J, van Boven-van Zomeren DM, Nooter K, Stoter G, Sparreboom A.

Anticancer Drugs. 2003 Mar;14(3):227-32.

PMID:
12634617
21.

Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel.

Smorenburg CH, Sparreboom A, Bontenbal M, Stoter G, Nooter K, Verweij J.

J Clin Oncol. 2003 Jan 15;21(2):197-202.

PMID:
12525510
22.

Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxel.

Loos WJ, Szebeni J, ten Tije AJ, Verweij J, van Zomeren DM, Chung KN, Nooter K, Stoter G, Sparreboom A.

Anticancer Drugs. 2002 Aug;13(7):767-75.

PMID:
12187334
23.

Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38.

Mathijssen RH, Verweij J, Loos WJ, de Bruijn P, Nooter K, Sparreboom A.

Br J Cancer. 2002 Jul 15;87(2):144-50.

24.

Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933.

van Zuylen L, Sparreboom A, van der Gaast A, Nooter K, Eskens FA, Brouwer E, Bol CJ, de Vries R, Palmer PA, Verweij J.

Eur J Cancer. 2002 May;38(8):1090-9.

PMID:
12008197
25.

Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel.

Gelderblom H, Verweij J, van Zomeren DM, Buijs D, Ouwens L, Nooter K, Stoter G, Sparreboom A.

Clin Cancer Res. 2002 Apr;8(4):1237-41.

26.

Structural identification and biological activity of 7-methyl-10,11-ethylenedioxy-20(S)-camptothecin, a photodegradant of lurtotecan.

Loos WJ, Verweij J, Kehrer DF, de Bruijn P, de Groot FM, Hamilton M, Nooter K, Stoter G, Sparreboom A.

Clin Cancer Res. 2002 Mar;8(3):856-62.

27.
28.

Determination of topotecan in human whole blood and unwashed erythrocytes by high-performance liquid chromatography.

Loos WJ, van Zomeren DM, Gelderblom H, Verweij J, Nooter K, Stoter G, Sparreboom A.

J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jan 5;766(1):99-105.

PMID:
11820300
29.

Impact of body-size measures on irinotecan clearance: alternative dosing recommendations.

Mathijssen RH, Verweij J, de Jonge MJ, Nooter K, Stoter G, Sparreboom A.

J Clin Oncol. 2002 Jan 1;20(1):81-7.

PMID:
11773157
30.

Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studies.

Gelderblom H, Loos WJ, Verweij J, van der Burg ME, de Jonge MJ, Brouwer E, Nooter K, Stoter G, Sparreboom A.

Eur J Cancer. 2002 Jan;38(1):205-13.

PMID:
11750851
31.
32.

The (ir)relevance of plasma protein binding of anticancer drugs.

Sparreboom A, Nooter K, Loos WJ, Verweij J.

Neth J Med. 2001 Oct;59(4):196-207. Review.

PMID:
11578795
33.

Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure.

de Jongh FE, Verweij J, Loos WJ, de Wit R, de Jonge MJ, Planting AS, Nooter K, Stoter G, Sparreboom A.

J Clin Oncol. 2001 Sep 1;19(17):3733-9.

PMID:
11533095
34.

Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.

Gelderblom H, Verweij J, Nooter K, Sparreboom A.

Eur J Cancer. 2001 Sep;37(13):1590-8. Review.

PMID:
11527683
35.

Does P-glycoprotein play a role in anticancer drug pharmacokinetics?

Sparreboom A, Nooter K.

Drug Resist Updat. 2000 Dec;3(6):357-363.

PMID:
11498403
36.

Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).

Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A.

Clin Cancer Res. 2001 Aug;7(8):2182-94. Review.

37.

Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles.

van Zuylen L, Karlsson MO, Verweij J, Brouwer E, de Bruijn P, Nooter K, Stoter G, Sparreboom A.

Cancer Chemother Pharmacol. 2001 Apr;47(4):309-18.

PMID:
11345647
38.

Development of multidrug-resistance convertors: sense or nonsense?

van Zuylen L, Nooter K, Sparreboom A, Verweij J.

Invest New Drugs. 2000 Aug;18(3):205-20. Review.

PMID:
10958589
39.

Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans.

van Zuylen L, Verweij J, Nooter K, Brouwer E, Stoter G, Sparreboom A.

Clin Cancer Res. 2000 Jul;6(7):2598-603.

40.

Mitomycins.

Verweij J, Sparreboom A, Nooter K.

Cancer Chemother Biol Response Modif. 1999;18:46-58. Review. No abstract available.

PMID:
10800477
41.

Liposomal lurtotecan (NX211): determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatography.

Loos WJ, Kehrer D, Brouwer E, Verweij J, de Bruijn P, Hamilton M, Gill S, Nooter K, Stoter G, Sparreboom A.

J Chromatogr B Biomed Sci Appl. 2000 Jan 28;738(1):155-63.

PMID:
10778937
42.

A genome-wide screening in Saccharomyces cerevisiae for genes that confer resistance to the anticancer agent cisplatin.

Burger H, Capello A, Schenk PW, Stoter G, Brouwer J, Nooter K.

Biochem Biophys Res Commun. 2000 Mar 24;269(3):767-74.

PMID:
10720490
43.

Determination of 5-fluorouracil in microvolumes of human plasma by solvent extraction and high-performance liquid chromatography.

Loos WJ, de Bruijn P, van Zuylen L, Verweij J, Nooter K, Stoter G, Sparreboom A.

J Chromatogr B Biomed Sci Appl. 1999 Dec 10;735(2):293-7.

PMID:
10670744
44.

Liquid chromatographic analysis and preliminary pharmacokinetics of methotrexate in cancer patients co-treated with docetaxel.

Sparreboom A, Loos WJ, Nooter K, Stoter G, Verweij J.

J Chromatogr B Biomed Sci Appl. 1999 Nov 26;735(1):111-9.

PMID:
10630896
45.

Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein.

Sparreboom A, Planting AS, Jewell RC, van der Burg ME, van der Gaast A, de Bruijn P, Loos WJ, Nooter K, Chandler LH, Paul EM, Wissel PS, Verweij J.

Anticancer Drugs. 1999 Sep;10(8):719-28.

PMID:
10573204
46.

Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function.

Gelderblom H, Verweij J, Brouwer E, Pillay M, de Bruijn P, Nooter K, Stoter G, Sparreboom A.

Drug Metab Dispos. 1999 Nov;27(11):1300-5.

PMID:
10534315
47.

Prediction of the systemic exposure to oral 9-amino-20(S)-camptothecin using single-sample analysis.

Sparreboom A, de Jonge MJ, Punt CJ, Loos WJ, Nooter K, Stoter G, Porro MG, Verweij J.

Drug Metab Dispos. 1999 Jul;27(7):816-20.

PMID:
10383926
48.

Distinct p53-independent apoptotic cell death signalling pathways in testicular germ cell tumour cell lines.

Burger H, Nooter K, Boersma AW, van Wingerden KE, Looijenga LH, Jochemsen AG, Stoter G.

Int J Cancer. 1999 May 17;81(4):620-8.

49.

Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.

Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, Pillay M, Nooter K, Stoter G, Verweij J.

Cancer Res. 1999 Apr 1;59(7):1454-7.

50.

Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatin.

Mathijssen RH, van Alphen RJ, de Jonge MJ, Verweij J, de Bruijn P, Loos WJ, Nooter K, Vernillet L, Stoter G, Sparreboom A.

Anticancer Drugs. 1999 Jan;10(1):9-16.

PMID:
10194542

Supplemental Content

Loading ...
Support Center